Management of inhibitors in persons with non-severe hemophilia A in the United States

Ming Y. Lim; Dunlei Cheng; Michael Recht; Christine L. Kempton; Nigel S. Key

doi:10.1002/ajh.26011

Management of inhibitors in persons with non-severe hemophilia A in the United States

Ming Y. Lim, Dunlei Cheng, Michael Recht, Christine L. Kempton, Nigel S. Key

Pediatrics

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	E9-E11
Journal	American Journal of Hematology
Volume	96
Issue number	1
DOIs	https://doi.org/10.1002/ajh.26011
State	Published - Jan 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26011

Cite this

@article{086ea2a8947740988df46c3f44587775,

title = "Management of inhibitors in persons with non-severe hemophilia A in the United States",

author = "Lim, {Ming Y.} and Dunlei Cheng and Michael Recht and Kempton, {Christine L.} and Key, {Nigel S.}",

note = "Funding Information: The authors acknowledge the 135+ ATHN‐affiliated Hemophilia Treatment Centers and their patients for contributing to the ATHNdataset. Ming Y Lim, MB BChir, received a 2015 HTRS/ATHN DREAM Award from the Hemostasis and Thrombosis Research Society (HTRS) and the American Thrombosis and Hemostasis Network (ATHN), which was supported by an independent medical educational grant from Shire. Funding Information: The authors acknowledge the 135+ ATHN-affiliated Hemophilia Treatment Centers and their patients for contributing to the ATHNdataset. Ming Y Lim, MB BChir, received a 2015 HTRS/ATHN DREAM Award from the Hemostasis and Thrombosis Research Society (HTRS) and the American Thrombosis and Hemostasis Network (ATHN), which was supported by an independent medical educational grant from Shire. Funding Information: M.R. has acted as a paid consultant to Bioverativ/Sanofi, CSL Behring, Genentech, Kedrion, NovoNordisk, Pfizer, Shire/Takeda, and uniQure. In addition, his organization has received research support from Bioverativ/Sanofi, BioMarin, Genentech, NovoNordisk, Shire/Takeda, Spark Therapeutics, and uniQure. He is on the Board of Directors of Foundation for Women and Girls with Blood Disorders and Partners in Bleeding Disorders, and is employed by the American Thrombosis and Hemostasis Network. C.L.K. received honoraria for participation in advisory boards with Spark Therapeutics, Pfizer, and Genentech and research support from Novo Nordisk. N.S.K. has received research funding from Takeda, Grifols, and Pfizer. In addition, he is on a steering committee for clinical trials for uniQure and grants review committee for NovoNordisk. M.Y.L. and D.C. report no conflict of interest. ",

year = "2021",

month = jan,

doi = "10.1002/ajh.26011",

language = "English (US)",

volume = "96",

pages = "E9--E11",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Management of inhibitors in persons with non-severe hemophilia A in the United States

AU - Lim, Ming Y.

AU - Cheng, Dunlei

AU - Recht, Michael

AU - Kempton, Christine L.

AU - Key, Nigel S.

N1 - Funding Information: The authors acknowledge the 135+ ATHN‐affiliated Hemophilia Treatment Centers and their patients for contributing to the ATHNdataset. Ming Y Lim, MB BChir, received a 2015 HTRS/ATHN DREAM Award from the Hemostasis and Thrombosis Research Society (HTRS) and the American Thrombosis and Hemostasis Network (ATHN), which was supported by an independent medical educational grant from Shire. Funding Information: The authors acknowledge the 135+ ATHN-affiliated Hemophilia Treatment Centers and their patients for contributing to the ATHNdataset. Ming Y Lim, MB BChir, received a 2015 HTRS/ATHN DREAM Award from the Hemostasis and Thrombosis Research Society (HTRS) and the American Thrombosis and Hemostasis Network (ATHN), which was supported by an independent medical educational grant from Shire. Funding Information: M.R. has acted as a paid consultant to Bioverativ/Sanofi, CSL Behring, Genentech, Kedrion, NovoNordisk, Pfizer, Shire/Takeda, and uniQure. In addition, his organization has received research support from Bioverativ/Sanofi, BioMarin, Genentech, NovoNordisk, Shire/Takeda, Spark Therapeutics, and uniQure. He is on the Board of Directors of Foundation for Women and Girls with Blood Disorders and Partners in Bleeding Disorders, and is employed by the American Thrombosis and Hemostasis Network. C.L.K. received honoraria for participation in advisory boards with Spark Therapeutics, Pfizer, and Genentech and research support from Novo Nordisk. N.S.K. has received research funding from Takeda, Grifols, and Pfizer. In addition, he is on a steering committee for clinical trials for uniQure and grants review committee for NovoNordisk. M.Y.L. and D.C. report no conflict of interest.

PY - 2021/1

Y1 - 2021/1

UR - http://www.scopus.com/inward/record.url?scp=85092302425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092302425&partnerID=8YFLogxK

U2 - 10.1002/ajh.26011

DO - 10.1002/ajh.26011

M3 - Letter

C2 - 32976635

AN - SCOPUS:85092302425

SN - 0361-8609

VL - 96

SP - E9-E11

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 1

ER -

Management of inhibitors in persons with non-severe hemophilia A in the United States

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this